Athira Pharma (NASDAQ:ATHA) Stock Rating Lowered by Mizuho

Mizuho cut shares of Athira Pharma (NASDAQ:ATHA) from an outperform rating to a neutral rating in a research report report published on Thursday, MarketBeat.com reports. They currently have $0.50 price target on the stock, down from their prior price target of $5.00.

ATHA has been the topic of a number of other research reports. JMP Securities cut Athira Pharma from an outperform rating to a market perform rating in a report on Wednesday, September 4th. Rodman & Renshaw downgraded Athira Pharma from a buy rating to a neutral rating in a research report on Wednesday, September 4th. Finally, BTIG Research cut Athira Pharma from a buy rating to a neutral rating in a research report on Wednesday, September 4th.

Athira Pharma Stock Down 7.4 %

Shares of ATHA stock opened at $0.43 on Thursday. Athira Pharma has a fifty-two week low of $0.43 and a fifty-two week high of $4.30. The business has a fifty day simple moving average of $2.49 and a 200-day simple moving average of $2.49. The stock has a market cap of $16.49 million, a P/E ratio of -0.14 and a beta of 2.90.

Athira Pharma (NASDAQ:ATHA) last announced its earnings results on Thursday, August 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.05. On average, sell-side analysts anticipate that Athira Pharma will post -2.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ATHA. Perceptive Advisors LLC increased its stake in Athira Pharma by 12.6% in the fourth quarter. Perceptive Advisors LLC now owns 5,402,964 shares of the company’s stock valued at $13,129,000 after purchasing an additional 605,686 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Athira Pharma by 25.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 550,353 shares of the company’s stock valued at $1,458,000 after buying an additional 111,759 shares during the period. Acadian Asset Management LLC grew its holdings in Athira Pharma by 281.5% in the 1st quarter. Acadian Asset Management LLC now owns 549,938 shares of the company’s stock valued at $1,505,000 after buying an additional 405,793 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Athira Pharma by 84.1% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 497,475 shares of the company’s stock valued at $1,363,000 after acquiring an additional 227,278 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Athira Pharma by 3.5% during the 2nd quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock worth $719,000 after acquiring an additional 9,164 shares during the period. 57.12% of the stock is currently owned by institutional investors and hedge funds.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.